BH-30236

A Phase 1/1b Open-Label, Dose Escalation, First-in- Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor, BH-30236, in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) or Higher-Risk Myelodysplastic Syndrome (HR-MDS)

Near Add Your Location

Sorting 18 by

Center of Excellence

Memorial Sloan Kettering Cancer Center
New York, NY
  • Accepting patients
  • Show Principal Investigator

Center of Excellence

MD Anderson Cancer Center
The University of Texas
Houston, TX
  • Accepting patients

Center of Excellence

Ohio State University Comprehensive Cancer Center
James Cancer Hospital and Solove Research Institute
Columbus, OH
  • Accepting patients

Center of Excellence

University of Wisconsin - Carbone Cancer Center
University of Wisconsin Health
Madison, WI
  • Accepting patients

Center of Excellence

Moffitt Cancer Center
Magnolia Campus
Tampa, FL
  • Accepting patients

Center of Excellence

City of Hope Comprehensive Cancer Center
Beckman Research Institute
Duarte, CA
  • Accepting patients

Center of Excellence

Fred Hutchinson Cancer Research Center
University of Washington Cancer Consortium / SCCA
Seattle, WA
  • Accepting patients
Memorial Sloan Kettering Westchester
West Harrison, NY
  • Accepting patients
  • Show Principal Investigator
Memorial Sloan Kettering Nassau
Uniondale, NY
  • Accepting patients
  • Show Principal Investigator
Memorial Sloan Kettering Monmouth
Middletown, NJ
  • Accepting patients
  • Show Principal Investigator

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.